Advertisement

Topics

Companies Related to "Coronary Artery Disease and Genetic Research: Indiana Health Study" [Most Relevant Company Matches] RSS

04:02 EST 19th November 2018 | BioPortfolio

Here are the most relevant search results for "Coronary Artery Disease and Genetic Research: Indiana Health Study" found in our extensive corporate database of over 50,000 company records.

Showing "Coronary Artery Disease Genetic Research Indiana Health Study" Companies 1–25 of 14,000+

Extremely Relevant

PlaqueTec Ltd.

PlaqueTec offers a first-of-its-kind catheter technology for cardiologists to routinely assess inflammation in the coronary artery, and better understand residual inflammatory risk. It has been proven to detect inflammatory molecules across the site of coronary artery disease (CAD), and can discriminate between patients with greater and lesser levels of co...


PLC Systems

PLC is a global leader in the development of products for performing a revolutionary new surgical procedure known as transmyocardial revascularization (TMR). TMR offers a completely new medical treatment option for patients who suffer from severe coronary artery disease. Coronary artery disease is the leading cause of death in the United States. Working with leading researchers and premier heart...

Rcadia Medical Imaging Ltd.

Rcadia Medical Imaging develops and markets automated image processing software products for blood vessel analysis in patients with suspected cardiovascular disease. The company's first FDA-cleared product, the COR Analyzer® System, provides fully automated analysis of Coronary CT angiography to enable the practical application of cCTA in detecting severe coronary artery disease. The COR Analyzer...


Relevant

Foxhollow Technologies

An estimated 12 million people in the U.S. alone have peripheral arterial disease (PAD). At least 40% of them also suffer from coronary artery disease (CAD). FoxHollow recently launched the SilverHawk® Plaque Excision System, a device that removes the plaque that commonly blocks arteries and interrupts blood flow. Unlike stenting and other methods of opening the artery, the SilverHawk removes the...

Rcadia Medical Imaging

Rcadia Medical Imaging develops and markets automated image processing software products for blood vessel analysis in patients with suspected cardiovascular disease. The company's first FDA-cleared product, the COR Analyzer® System, provides fully automated, real-time analysis of Coronary CT angiography to enable the practical application of cCTA in detecting severe coronary artery disease. The C...

Rcadia Medical Imaging, Ltd.

Rcadia Medical Imaging develops and markets automated image processing software products for blood vessel analysis in patients with suspected cardiovascular disease. The company's first FDA-cleared product, the COR Analyzer® System, provides fully automated, real-time analysis of Coronary CT angiography to enable the practical application of cCTA in detecting severe coronary artery disease. The C...

Cappella, Inc.

Cappella, Inc. is a medical device company, developing novel solutions for the treatment of complex Coronary Artery Disease (CAD), specifically bifurcation disease. Cappella’s initial product, the Sideguard® Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a straightforward, effective solution that focuses on treating...

Cappella Inc.

Cappella, Inc. is a medical device company, developing novel solutions for the treatment of complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. Cappella's initial product, the Sideguard® Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a straightforward, effective solution that focuses on treating the sidebranch of diseased coronary ...

HeartFlow, Inc.

HeartFlow, Inc., based in Redwood City, Calif., is pioneering technology designed to help physicians noninvasively diagnose coronary artery disease, improve patient outcomes and reduce health care costs. For more information visit www.heartflow.com.

Interleukin Genetics

Interleukin Genetics aims to be the world leader in understanding the genetics of inflammation, one of the body's most important defense mechanisms. Our scientists and clinicians study how common variations in several genes, especially three (known as IL-1a, IL-1b, and IL-1RN) affect an individual's response to the injuries caused by chronic diseases or disabilities such as coronary artery disease...

EPIXMedical Incorporated

EPIX's goal is to transform the management and diagnosis of vascular disease through the development of targeted MRI contrast agents. Based on its core, proprietary technology, EPIX is advancing its pipeline of products such as MS-325, the Company's lead MRI contrast agent currently in Phase III trials. MS-325 is also in development to help diagnose coronary artery disease, breast cancer, female s...

EPIX Medical Incorporated

Based on its core, proprietary technology, EPIX is advancing its pipeline of products such as MS-325, the Company's lead MRI contrast agent currently in Phase III trials. MS-325 is also in development to help diagnose coronary artery disease, breast cancer, female sexual arousal dysfunction, atherosclerosis and myocardial perfusion. In addition to MS-325, EPIX's pipeline includes a new class of MR...

Fairbanks Institute for Healthy Communities

The Fairbanks Institute for Healthy Communities is a not-for-profit organization working to improve community health by conducting longitudinal cohort studies of the Central Indiana population (The Indiana Health Study) that will enable research that speeds the development of personalized medicine and improvements in patient outcomes. The Fairbanks Institu...

Analytics 4 Life

Analytics 4 Life is pioneering digital health using artificial intelligence to develop a completely new form of medical imaging. With an initial focus on coronary artery disease, Analytics 4 Life is advancing a novel, radiation-free, and exercise-free cardiac imaging technology aimed at improving existing care pathways. Analytics 4 Life is based in Toronto...

Pathway Medical Technologies Inc.

Pathway Medical Technologies, Inc. (Pathway), located in Redmond, Washington was founded in 1998 to design, develop and manufacture innovative medical devices intended for the treatment of arterial disease. The company’s initial focus is on peripheral artery disease (PAD).According to the American Heart Association, peripheral artery disease affects 8 – 12 million in the U.S. PAD prevalence in...

Cappella Medical Devices Limited

Cappella, Inc. develops novel solutions for the treatment of complex coronary artery disease (CAD) - specifically bifurcation disease. Cappella’s Sideguard® coronary sidebranch technology offers interventional cardiologists a straightforward, effective, solution that focuses on treating the sidebranch of diseased coronary arteries first, rather tha...

Interleukin Genetics, Inc.

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intell...

Cappella Medical Devices Ltd

Cappella, Inc. is a medical device company that develops novel solutions for the treatment of complex coronary artery disease (CAD) focused on protecting the coronary sidebranch arteries. Cappella’s Sideguard® coronary sidebranch technology offers interventional cardiologists a straightforward, effective, and easy to use solution that preserves the ...

Nanobiotech

NanoBiotech is a life science company that discovers, develops, and manufactures novel nanobiotics designed to improve people's health through the treatment of diseases associated with pathological calcification, inflammation and nanobacterial infections. Our Founders’ pioneering research has established the role of Nanobacteria in pathological calcification: particularly in the development o...

Genetic Analysis

Genetic Analysis has developed and launched the first gene-based routine test for the mapping and diagnosis of diseases related to dysbiosis and imbalances in the bacteria in the digestive system. The company markets the GA-map™ technology to three market segments: commercial routine testing, pharma companies and the research market. Genetic Analysis ...

Healthy Life Screening

Located in Akron, Ohio, Healthy Life Screening was started in 2006 offering a range of preventive health screens on asymptomatic individuals for the presence of cardiovascular disease. The screening consists of five tests: left ventricle dysfunction, peripheral artery disease, abdominal aortic, carotid artery screening (including carotid intima-media thick...

CathWorks

CathWorks is a medical technology company focused on applying its advanced computational science platform to optimize PCI therapy decisions and elevate coronary angiography from visual assessment to an objective FFR-based decision-making tool for physicians. FFR-guided PCI decision-making is proven to provide significant clinical benefits for patients with...

Cappella Medical Devices, Ltd.

Cappella, Inc. is a medical device company, developing novel solutions for the treatment of complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. Cappella’s initial product, the Sideguard® Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a straightforward, effective solution that focuses...

The Hope Heart Institute

The Hope Heart Institute was founded in 1959 by Lester R. Sauvage, MD, a world-renowned cardiovascular surgeon and research scientists. Dr. Sauvage and The Hope earned international recognition in 1962 through pioneering coronary artery bypass graft (CABG) surgery. Today, The Hope's research remains at the forefront of the cardiovascular field—and our health education publications reach nearly 5...

Ischemix

Ischemix is a privately-held drug discovery company with a portfolio of small molecule therapeutic compounds. The first of these compounds is targeted to reduce cell death and organ damage due to initial interruption and subsequent resumption of blood flow associated with cardiac surgeries and interventional procedures such as percutaneous coronary interve...


More From BioPortfolio on "Coronary Artery Disease and Genetic Research: Indiana Health Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks